Want to see IN:INDOCO full AI Analyst Report?
INDOCO Stock Chart & Stats
₹238.85
₹4.72(1.94%)
At close: 4:00 PM EDT
₹238.85
₹4.72(1.94%)
Day’s Range― - ―
52-Week Range₹163.70 - ₹317.10
Previous CloseN/A
Volume80.97K
Average Volume (3M)44.37K
Market Cap
₹23.02B
Enterprise Value₹25.64K
Total Cash (Recent Filing)₹329.90M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)858.7
Beta1.08
Next Earnings
Nov 05, 2026EPS Estimate
0.9Next Dividend Ex-DateN/A
Dividend Yield0.08%
Share Statistics
EPS (TTM)0.29
Shares Outstanding92,303,604
10 Day Avg. Volume59,847
30 Day Avg. Volume44,370
Financial Highlights & Ratios
PEG Ratio-0.63
Price to Book (P/B)1.55
Price to Sales (P/S)0.79
P/FCF Ratio-12.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)6.48
Revenue Forecast (FY)₹20.51B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthPositive latest-year revenue growth indicates that Indoco continues to expand product sales despite recent profitability pressure. Sustained top-line progression can support operating recovery, improve scale across its portfolio, and strengthen the company’s ability to absorb fixed costs over the next several quarters.
Gross MarginA gross margin of roughly 41%, with improvement versus FY2024, provides a meaningful economic base for the business. If Indoco can control operating costs and improve execution, this product-level profitability could support margin recovery and better conversion of revenue into earnings.
Diversified Pharma PlatformIndoco’s combination of formulations, APIs, domestic brands, international offerings, manufacturing, and R&D creates several avenues for commercial activity. This broader platform can reduce reliance on one therapy area or market and provides a foundation for product expansion over the medium term.
Bears Say
Losses And Margin CompressionTwo consecutive years of net losses and an EBIT margin near 0.8% show that revenue growth is not currently translating into adequate operating profitability. Continued margin compression could weaken reinvestment capacity and make earnings recovery dependent on substantial cost or execution improvements.
Rising LeverageThe sharp increase in debt-to-equity has reduced Indoco’s financial flexibility while returns have turned negative. Higher leverage can constrain capital allocation, increase the burden of servicing obligations, and leave less room to fund growth or withstand continued weakness in profitability.
Weak Free Cash FlowDeeply negative free cash flow over the last two years indicates that operating cash generation has not covered investment and other cash requirements. This weak conversion limits internally funded growth, increases dependence on financing, and heightens execution risk until cash generation becomes consistently positive.
Indoco Remedies Limited News
INDOCO FAQ
What was Indoco Remedies Limited’s price range in the past 12 months?
Indoco Remedies Limited lowest stock price was ₹163.70 and its highest was ₹317.10 in the past 12 months.
What is Indoco Remedies Limited’s market cap?
Indoco Remedies Limited’s market cap is ₹23.02B.
When is Indoco Remedies Limited’s upcoming earnings report date?
Indoco Remedies Limited’s upcoming earnings report date is Nov 05, 2026 which is in 45 days.
How were Indoco Remedies Limited’s earnings last quarter?
Indoco Remedies Limited released its earnings results on Jul 28, 2026. The company reported ₹7.1 earnings per share for the quarter, beating the consensus estimate of -₹3.6 by ₹10.7.
Is Indoco Remedies Limited overvalued?
According to Wall Street analysts Indoco Remedies Limited’s price is currently Overvalued.
Does Indoco Remedies Limited pay dividends?
Indoco Remedies Limited pays a Annually dividend of ₹0.2 which represents an annual dividend yield of 0.08%. See more information on Indoco Remedies Limited dividends here
What is Indoco Remedies Limited’s EPS estimate?
Indoco Remedies Limited’s EPS estimate is 0.9.
How many shares outstanding does Indoco Remedies Limited have?
Indoco Remedies Limited has 92,303,604 shares outstanding.
What happened to Indoco Remedies Limited’s price movement after its last earnings report?
Indoco Remedies Limited reported an EPS of ₹7.1 in its last earnings report, beating expectations of -₹3.6. Following the earnings report the stock price went down -7.931%.
Which hedge fund is a major shareholder of Indoco Remedies Limited?
Currently, no hedge funds are holding shares in IN:INDOCO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Indoco Remedies Limited
Indoco Remedies Limited, an Indian pharmaceutical company founded in Mumbai in 1945 (originally known as Indo Continental Trading Company), operates globally, manufacturing and distributing a broad spectrum of finished drug formulations and active pharmaceutical ingredients (APIs). The company's extensive product portfolio addresses diverse therapeutic areas: Respiratory conditions: with offerings like Karvol Plus, Febrex Plus, and Tuspel. Oral and dental care (stomatologicals): including Sensodent-K, Sensoform Toothpaste, the Rexidin series, and Snowdent. Gastrointestinal ailments: featuring products such as Carmicide, Cyclopam, and Nosic. Pain relief/analgesics: exemplified by Lignox and T-lac. Ophthalmic and otic solutions: comprising items like Renolen, Dexoren – S, and the Mofloren range. Vitamins, minerals, and nutritional supplements: such as Methycal, MCBM DHA, and Apispur. Urological treatments: including Carmicide and Cital. Dermatological preparations: like Cloben G and Scabex. Anti-infective agents: represented by ATM. Blood-related therapies: such as Hemsyl. Gynecological health products: including MCBM 69 and D Chiro. Anti-haemorrhoidal treatments: with Spear. Beyond its pharmaceutical manufacturing, Indoco Remedies provides comprehensive analytical services. These include impurity profiling, particle size analysis, heavy metal analysis, polymorphism studies, compatibility and stability assessments (like extractables/leachables and lyophilization), and advanced chromatographic method development and validation. Furthermore, the company offers a suite of engineering and project management services. This covers architectural and structural design, mechanical and electrical engineering, lighting solutions, control system integration, piping design, data transfer systems, and holistic project and construction management for process facilities. Indoco Remedies serves a wide range of medical professionals, from general practitioners and pediatricians to specialized consultants like dentists, cardiologists, diabetologists, endocrinologists, gynaecologists, and ophthalmologists.
Technical Analysis
Alembic Pharmaceuticals Limited
―
Hikal Limited
―
Morepen Laboratories Limited
―
Solara Active Pharma Sciences Ltd.
―
Unichem Laboratories Limited
―